Coordinatore | UNIVERSITE PAUL SABATIER TOULOUSE III
Organization address
address: ROUTE DE NARBONNE 118 contact info |
Nazionalità Coordinatore | France [FR] |
Totale costo | 45˙000 € |
EC contributo | 45˙000 € |
Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
Code Call | FP7-PEOPLE-2010-RG |
Funding Scheme | MC-ERG |
Anno di inizio | 2011 |
Periodo (anno-mese-giorno) | 2011-01-01 - 2013-12-31 |
# | ||||
---|---|---|---|---|
1 |
UNIVERSITE PAUL SABATIER TOULOUSE III
Organization address
address: ROUTE DE NARBONNE 118 contact info |
FR (TOULOUSE CEDEX 9) | coordinator | 45˙000.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Current transdermal drug delivery relies primarily upon occlusive patches, and is now considered to be a mature technology. This method is capable of delivering drugs, reducing side effects of oral administration and poor compliance due to the need for frequent administration. However, the disadvantages of transdermal delivery systems have been skin irritation, relatively high manufacturing costs and less-than-ideal cosmetic appearance. Regardless of the transdermal drug delivery system in development, the patient acceptability from an aesthetic point of view and lack of irritation perspective remain nowadays the main focus for the newer products entering the market.
The originality of the project is reflected in idea on formulating a simplest transdermal drug delivery system constituted by a monolayer structure which includes the backing, adhesive and drug reservoir functions and which can be easily removed from the skin after use. The approach consists of using biocompatible natural polymers for the elaboration of the bioadhesive film and the specific surface functionalization processes for achievement of the desired surface characteristics (adhesion and easy skin removal properties). The functionalization of the biocompatible drug loaded matrix by grafting stimuli responsive polymers (e.g. temperature, light) will allow to introduce a ‘switch’ mechanism on the surface for an easy removal on demand. Thus, a transdermal device, containing a natural biocompatible matrix with conventional biopolymers properties, but with advanced stimuli responsiveness properties will be created. This new transdermal device will show application for osteoporosis treatment.
This project, based on the combination of surface modification methods (plasma treatment, etc), is at the interface of several disciplines: material chemistry, surface chemistry, pharmaceutics, etc.'
Transdermal drug delivery (TDD) has made an important contribution to medical practice as an alternative to oral delivery and hypodermic injections. Using novel enhancement strategies, transdermal delivery is poised to significantly increase its impact on medicine.